
Aarti Pharmalabs: Q2 FY27 Earnings Review
Aarti’s investments are translating into API sales. The next test is for second-half sales to convert into cash while new assets add costs.
Read our featured deep-dive into a business.

INSIGHTS
FY26 revenue grew 61% to Rs. 3,107 Cr. with EBITDA/tonne rising to Rs. 67,625, driven by shift to specialised transformer wires.
Supa expansion nearly doubles capacity, backed by structural transformer demand and 97% repeat customer revenue.
Operating cash flow turned negative (-Rs. 65 Cr.) in FY26 as inventory and receivables ballooned despite profit growth.
Arhan Mandapwala - Author
10 min read

Aarti’s investments are translating into API sales. The next test is for second-half sales to convert into cash while new assets add costs.

Subex delivered another quarter of revenue growth while keeping its operating margin near 21% despite annual wage increases.

GHCL has made tangible progress in diversification, but the November call did not establish a recovery in soda ash profitability.
Weekly Newsletter
Get market insights & stock picks every week.
Read on Substack
Read our deep-dive reports on Substack.